InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| CR3022-derived Anti-SARS-CoV2 RBD mAbs, human & mouse isotypes | Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals... | 2022 | Sci Rep. | Thomas S.N. et al. | DOI: 10.1038/s41598-022-12869-z |
| Primocin® | The unfolded protein response to PI*Z alpha-1 antitrypsin in human hepatocell... | 2022 | Hepatol Commun. | Lu Y. et al. | DOI: 10.1002/hep4.1997 |
| LPS-EB VacciGrade™ | The unfolded protein response to PI*Z alpha-1 antitrypsin in human hepatocell... | 2022 | Hepatol Commun. | Lu Y. et al. | DOI: 10.1002/hep4.1997 |
| Nigericin | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
| Nano-SiO2 | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
| Poly(dA:dT) | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
| FSL-1 | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
| Pam3CSK4 | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
| LPS-EB (LPS from E. coli O111:B4) | NLRP3 licenses NLRP11 for inflammasome activation in human macrophages. | 2022 | Nat Immunol. | Gangopadhyay A. et al. | DOI: 10.1038/s41590-022-01220-3 |
| Alhydrogel® adjuvant 2% | Distinct effects of different adjuvants in the mouse model of allergic airway... | 2022 | Asian Pac J Allergy Immunol. | Shin H.S. et al. | DOI: 10.12932/AP-301219-0729 |
| ASC-GFP Reporter Monocytes | Extracellular Inflammasome Particles Are Released After Marathon Running and ... | 2022 | Front Physiol. | Kogel A. et al. | DOI: 10.3389/fphys.2022.866938 |
| Recombinant human IL-12 protein | Mitochondrial damage-associated molecular patterns trigger arginase-dependent... | 2022 | Cell Rep. | Westhaver L.P. et al. | DOI: 10.1016/j.celrep.2022.110847 |
| ODN 1668 - TLR9 ligand | Mitochondrial damage-associated molecular patterns trigger arginase-dependent... | 2022 | Cell Rep. | Westhaver L.P. et al. | DOI: 10.1016/j.celrep.2022.110847 |
| Recombinant human IL-18 protein | Mitochondrial damage-associated molecular patterns trigger arginase-dependent... | 2022 | Cell Rep. | Westhaver L.P. et al. | DOI: 10.1016/j.celrep.2022.110847 |
| RAW-Lucia™ ISG Cells | STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robus... | 2022 | Nat Mater. | Dane E.L. et al. | DOI: 10.1038/s41563-022-01251-z |
| THP1-Lucia™ ISG Cells | STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robus... | 2022 | Nat Mater. | Dane E.L. et al. | DOI: 10.1038/s41563-022-01251-z |
| QUANTI-Luc™: Luciferase Detection Reagent | STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robus... | 2022 | Nat Mater. | Dane E.L. et al. | DOI: 10.1038/s41563-022-01251-z |
| RAW-Blue™ Cells | Human corneal stromal stem cells express anti-fibrotic microRNA-29a and 381-5... | 2022 | J Adv Res. | Yam G.H. et al. | DOI: 10.1016/j.jare.2022.05.008 |
| Normocin® - Antimicrobial Reagent | Human corneal stromal stem cells express anti-fibrotic microRNA-29a and 381-5... | 2022 | J Adv Res. | Yam G.H. et al. | DOI: 10.1016/j.jare.2022.05.008 |
| THP1-Dual™ Cells | DDX41 is required for cGAS-STING activation against DNA virus infection. | 2022 | Cell Rep. | Singh R.S. et al. | DOI: 10.1016/j.celrep.2022.110856 |